Charles River Labs stock holds near yearly high as analysts see limited upside

Charles River Labs stock remains close to its recent yearly high as of September 1, 2026, while analysts see only modest further upside based on a consensus target price. For investors, the balance between growth prospects and valuation is now key.

Charles River Labs stock (ISIN US1591881009) is trading near its recent yearly high as of September 1, 2026, with the company valued at about USD 8.2 billion in market capitalization according to an overview of laboratory-service peers updated on September 2, 2026.

Analyst consensus signals limited upside

According to a comparison of contract research peers compiled by MarketBeat, Charles River Laboratories International carried a consensus target price of USD 255.65 as of early September 2026, implying a potential downside of 9.42% from the then-current share price level in that analysis.

The same MarketBeat overview, updated on September 2, 2026, shows that analysts assign Charles River Laboratories International an average rating score of 2.69, based on 1 sell rating, 3 hold ratings and 12 buy ratings, underlining that the stock is broadly viewed positively but not without reservations on valuation.

Market valuation and peer context

An overview of sector valuations compiled by Macrotrends lists Charles River Laboratories with a market capitalization of USD 8.198 billion and a price to earnings ratio of 16.06 as of a recent data update prior to September 2, 2026.

Compared with peers in the contract research and life science services space, analysts cited in the MarketBeat comparison see a higher rating score of 2.88 for IQVIA and consider IQVIA more favorable than Charles River Laboratories, even though both companies trade above book value and are covered by a similar mix of buy and hold recommendations.

Preclinical services underpin growth

Charles River Laboratories International focuses on preclinical and early-stage development services, including safety assessment, discovery and biologics testing solutions that support pharmaceutical and biotech clients in bringing new therapies to market.

The company also provides specialty toxicology and pathology services as well as bioanalytical testing, which together aim to shorten development timelines for complex biologics and small-molecule drugs and help clients comply with regulatory requirements.

Stock valuation and investor view

With a market capitalization of USD 8.198 billion as of a recent data snapshot before September 2, 2026, and a price to earnings ratio of 16.06, Charles River Labs stock trades at a valuation that, according to publicly available analyst comparisons, prices in continued earnings growth but leaves only limited upside to the consensus target price of USD 255.65.

For investors, the key question is whether the company can sustain enough growth in its preclinical and laboratory services to justify this valuation, particularly in light of the mixed analyst rating balance that combines one sell, three hold and twelve buy opinions in the latest MarketBeat compilation.

Key data for Charles River Labs stock

• Company: Charles River Laboratories International, Inc.
• ISIN: US1591881009
• Ticker: CRL
• Trading venue: NYSE
• Market capitalization: 8.198 billion USD (as of recent data before September 2, 2026)
• Sector / Industry: Health Care / Life Sciences Tools and Services
• Index membership: S&P 500